The trajectory of Sildenafil presents a nuanced case for stakeholders in the pharmaceutical sector. While initially a blockbuster success, creating billions, the exclusivity expiration and the subsequent flood of https://knockoff592542.bluxeblog.com/74223260/the-little-copyright-and-big-pharma-a-risky-play